Status:
RECRUITING
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Lead Sponsor:
Nuwacell Biotechnologies Co., Ltd.
Conditions:
Parkinson Disease
Eligibility:
All Genders
40-75 years
Phase:
PHASE1
Brief Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
Detailed Description
Parkinson's disease (PD) is a common neurodegenerative disease in the middle-aged and elderly. It is the "third killer" of the middle-aged and elderly after tumors and cardiovascular and cerebrovascul...
Eligibility Criteria
Inclusion
- Ages between 40 and 75 years;
- Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;
- Disease history over 5 years;
- Stable dose of dopamine treatment;
- Able to undergo PET/CT/MRI detection;
Exclusion
- Patients who have previously undergone brain surgery;
- Past use of stem cell therapy or participation in stem cell clinical research;
- Cognitive impairment;
- History of mental disorders;
- Patients with other serious systemic diseases;
- Past or current metastatic malignant tumors.
Key Trial Info
Start Date :
June 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06978920
Start Date
June 6 2025
End Date
December 1 2028
Last Update
August 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of USTC
Hefei, Anhui, China